Join
Live feed
·
PRReleasevia Quantisnow
Lyell Immunopharma Inc. logo

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

ByQuantisnow·Wall Street's wire, on your screen.
LYEL· Lyell Immunopharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LYEL (Lyell Immunopharma Inc.) and more on Quantisnow.